Scotgold Resources Limited (AIM: SGZ), Scotland’s first commercial gold producer, announces an operational and corporate update f or its Cononish Gold and Silver Mine in Scotland (“Cononish”).
Scotgold Resources Limited (AIM: SGZ), Scotland’s first commercial gold producer, announces an operational and corporate update f or its Cononish Gold and Silver Mine in Scotland (“Cononish”).
Scotgold Resources will raise £2.5 million to fund growth plans that include exploration in the Scottish Highlands.
Scotgold Resources Limited (“Scotgold” or the “Company”) (AIM: SGZ), the gold exploration and production company focused on Scotland , is pleased to announce that following the accelerated bookbuild which was
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, is pleased to announce the successful completion of its third Process Qualification (“PQ”) run of
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has made significant progress towards the practical use of its Chimeric Bait Receptor (“CBR”) platform technology, designed to program immune cells to
The stunningly beautiful Loch Lomond & The Trossachs National Park in Scotland is a must-see. It is located at the base of the Highlands in the southwest.
One of America’s Top Bone Marrow Transplant and Oncology Doctors Joins Hemogenyx Pharmaceuticals as Medical Director
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that it has achieved proof of concept (“POC”) for its
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, has received notification from the Food and Drugs Administration (“FDA”) that the proposed pre-Investigational
Partnership with WuXi Advanced Therapies to manufacture lentiviral vectors for phase I trial of cutting edge HEMO-CAR-T programme
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases.